Close Menu

NIH

The company is currently working on multiple infectious disease products, including a panel for sexually transmitted infections and one for SARS-CoV-2.

The company's contract with the NIH offered $12 million total and after initial test verification, Fluidigm will receive approximately $11 million.

Funding from RADx and NIAID will enable the scale-up of multiplexed viral detection microarrays to 4 million tests per month.

The company's RaPID platform detects infections directly from a blood sample and can provide results in three hours.

The PCR diagnostic device is a palm-size, single-use, disposable device that detects N. gonorrhoeae and determines if it's susceptible to an antibiotic.

The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.

A consortium convened by Friends of Cancer Research has made progress in quantifying sources of TMB assay discordance and created a new test-alignment software tool.

The forum will gather information on issues surrounding SARS-CoV-2 testing and diagnostics from federal officials and the private sector.

Tasso said academic medical institutions, government agencies, cancer centers, and pharma organizations are already using its blood collection devices.

The firm's test detects DNA from tick-borne bacteria directly from a patient's blood, and clinical studies are planned for the 2021 tick season.

Pages